Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome

NCT ID: NCT02626741

Last Updated: 2015-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether meal replacement, SlimWell ®, is effective in the treatment of obesity patients with metabolic syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants are divided into two groups: intervention group and control group. In the intervention group, the participants receive a meal replacement plus life style modification. In the control group, the participants receive only life style modification.

Sample size calculation is 69 participants per group. Primary outcome is to compare the weight loss between the intervention group and control group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Obesity-Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

meal replacement group

the participants receive a meal replacement plus life style modification

Group Type EXPERIMENTAL

meal replacement group

Intervention Type DIETARY_SUPPLEMENT

The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

control group

Intervention Type BEHAVIORAL

The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

control group

the participants receive life style modification only.

Group Type EXPERIMENTAL

control group

Intervention Type BEHAVIORAL

The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

meal replacement group

The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

Intervention Type DIETARY_SUPPLEMENT

control group

The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SlimWell only life style modification

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index more than or equal to 25 kg/m2
* Patients with metabolic syndrome
* Patients who are on anti-hypertensive drugs, oral hypoglycemic drugs and lipid lowering drugs.

Exclusion Criteria

* Uncontrolled diabetes patients
* Patients with gastrointestinal abnormalities
* Patients with cardiovascular diseases
* Patients with hematologic disorders
* Patients with Glomerular filtration rate less than 60 ml/min/1.73m2
* Patients with drug or alcohol abuse
* Pregnancy and lactation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mahidol University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kusuma Chaiyasoot, MD

Role: PRINCIPAL_INVESTIGATOR

Mahidol University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine Siriraj Hospital, Mahidol University

Bangkok, Bangkok, Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kusuma Chaiyasoot, MD

Role: CONTACT

Phone: +66819304743

Email: [email protected]

Preyanuj Yamwong, MD

Role: CONTACT

Phone: +66897750773

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kusuma Chaiyasoot, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Leader NJ, Ryan L, Molyneaux L, Yue DK. How best to use partial meal replacement in managing overweight or obese patients with poorly controlled type 2 diabetes. Obesity (Silver Spring). 2013 Feb;21(2):251-3. doi: 10.1002/oby.20057.

Reference Type BACKGROUND
PMID: 23404963 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

647-2557-EC4

Identifier Type: -

Identifier Source: org_study_id